| A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS U Keilholz, A Letsch, A Busse, AM Asemissen, S Bauer, IW Blau, ... Blood, The Journal of the American Society of Hematology 113 (26), 6541-6548, 2009 | 387 | 2009 |
| Expression of the stem cell markers nestin and CD133 on circulating melanoma cells A Fusi, U Reichelt, A Busse, S Ochsenreither, A Rietz, M Maisel, ... Journal of Investigative Dermatology 131 (2), 487-494, 2011 | 85 | 2011 |
| Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits A Busse, M Kraus, IK Na, A Rietz, C Scheibenbogen, C Driessen, IW Blau, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2008 | 84 | 2008 |
| Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma R Schuster, NE Bechrakis, A Stroux, A Busse, A Schmittel, ... Clinical cancer research 13 (4), 1171-1178, 2007 | 84 | 2007 |
| Role of TGF-β in melanoma A Busse, U Keilholz Current pharmaceutical biotechnology 12 (12), 2165-2175, 2011 | 82 | 2011 |
| Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia S Heesch, N Goekbuget, A Stroux, JO Tanchez, C Schlee, T Burmeister, ... haematologica 95 (6), 942, 2010 | 67 | 2010 |
| Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma A Busse, AM Asemissen, A Nonnenmacher, F Braun, S Ochsenreither, ... European Journal of Cancer 47 (5), 690-696, 2011 | 64 | 2011 |
| Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2 R Godal, U Keilholz, L Uharek, A Letsch, AM Asemissen, A Busse, IK Na, ... Blood 107 (8), 3205-3211, 2006 | 60 | 2006 |
| Fractionated irradiation can induce functionally relevant multidrug resistance gene and protein expression in human tumor cell lines D Bottke, D Koychev, A Busse, K Heufelder, T Wiegel, E Thiel, ... Radiation research 170 (1), 41-48, 2008 | 50 | 2008 |
| Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study) A Fusi, S Collette, A Busse, S Suciu, A Rietz, M Santinami, WHJ Kruit, ... European Journal of Cancer 45 (18), 3189-3197, 2009 | 49 | 2009 |
| Characterization of small spheres derived from various solid tumor cell lines: are they suitable targets for T cells? A Busse, A Letsch, A Fusi, A Nonnenmacher, D Stather, S Ochsenreither, ... Clinical & experimental metastasis 30, 781-791, 2013 | 48 | 2013 |
| Efficiency of the four proteasome subtypes to degrade ubiquitinated or oxidized proteins J Abi Habib, E De Plaen, V Stroobant, D Zivkovic, MP Bousquet, ... Scientific reports 10 (1), 15765, 2020 | 45 | 2020 |
| Wilms’ tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome A Busse, N Gökbuget, JM Siehl, D Hoelzer, S Schwartz, A Rietz, E Thiel, ... Annals of hematology 88, 1199-1205, 2009 | 45 | 2009 |
| Expression of the stem cell marker nestin in peripheral blood of patients with melanoma A Fusi, S Ochsenreither, A Busse, A Rietz, U Keilholz British Journal of Dermatology 163 (1), 107-114, 2010 | 42 | 2010 |
| “Wilms Tumor Protein 1”(WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell … S Ochsenreither, A Fusi, A Busse, S Bauer, C Scheibenbogen, D Stather, ... Journal of immunotherapy 34 (1), 85-91, 2011 | 41 | 2011 |
| Prognostic relevance of circulating tumor cells in metastatic uveal melanoma R Schuster, NE Bechrakis, A Stroux, A Busse, A Schmittel, E Thiel, ... Oncology 80 (1-2), 57-62, 2011 | 40 | 2011 |
| Relative quantification of TCR Vbeta-chain families by real time PCR for identification of clonal T-cell populations S Ochsenreither, A Fusi, A Busse, D Nagorsen, D Schrama, J Becker, ... Journal of translational medicine 6, 1-8, 2008 | 39 | 2008 |
| Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer UM Demel, M Böger, S Yousefian, C Grunert, L Zhang, PW Hotz, ... The Journal of Clinical Investigation 132 (9), 2022 | 36 | 2022 |
| Adaptive T-cell immunity controls senescence-prone MyD88-or CARD11-mutant B-cell lymphomas M Reimann, J Schrezenmeier, P Richter-Pechanska, A Dolnik, TP Hick, ... Blood, The Journal of the American Society of Hematology 137 (20), 2785-2799, 2021 | 33 | 2021 |
| What does the pipeline promise about upcoming biosimilar antibodies in oncology? A Busse, D Lüftner Breast Care 14 (1), 10-16, 2019 | 28 | 2019 |
